SCNI and 2F5 Related Headlines
Go Back- Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
- Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
- Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
- Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
- Scinai Immunotherapeutics receives Nasdaq bid price deficiency notice
- Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
- Scinai seeks €12 million EU grant for autoimmune drug development
- Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept
- Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm
- Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet
- Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"
- Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025
SCNI and 2F5 Related Press Releases
Go Back- Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
- Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
- Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
- Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
- Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
- Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept
- Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm
- Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet
- Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"
- Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025
SCNI and 2F5 Related SEC Filings
Go Back- Form 6-K Scinai Immunotherapeutic For: Jun 08
- Form EFFECT Scinai Immunotherapeutic
- Form 424B3 Scinai Immunotherapeutic
- Form 6-K Scinai Immunotherapeutic For: May 12
- Form F-3 Scinai Immunotherapeutic
- Form 6-K Scinai Immunotherapeutic For: Dec 31
- Form 6-K Scinai Immunotherapeutic For: Apr 27
- Form 20-F Scinai Immunotherapeutic For: Dec 31
- Form 3 Scinai Immunotherapeutic For: Mar 18 Filed by: Mark Elad
- Form 6-K Scinai Immunotherapeutic For: Mar 23
- Form 6-K Scinai Immunotherapeutic For: Mar 19
- Form 3 Scinai Immunotherapeutic For: Mar 18 Filed by: MARGOLIN YAEL
- Form 3 Scinai Immunotherapeutic For: Mar 18 Filed by: Ben-Or Uri
- Form 3 Scinai Immunotherapeutic For: Mar 18 Filed by: Moed Samuel J
- Form 3 Scinai Immunotherapeutic For: Mar 18 Filed by: GERMAIN MARK
- Form 3 Scinai Immunotherapeutic For: Mar 18 Filed by: Green Jay
- Form 3 Scinai Immunotherapeutic For: Mar 18 Filed by: Reichman Amir
- Form 3 Scinai Immunotherapeutic For: Mar 18 Filed by: Raviv Adi
- Form 6-K Scinai Immunotherapeutic For: Feb 25
- Form SCHEDULE 13G/A Scinai Immunotherapeutic Filed by: STONE DANIEL E.
- Form 6-K Scinai Immunotherapeutic For: Feb 17
- Form 6-K Scinai Immunotherapeutic For: Dec 23
- Form 6-K Scinai Immunotherapeutic For: Dec 02
- Form 6-K Scinai Immunotherapeutic For: Nov 13
- Form 6-K Scinai Immunotherapeutic For: Nov 13
- Form S-8 Scinai Immunotherapeutic
- Form 6-K Scinai Immunotherapeutic For: Oct 06
- Form 424B3 Scinai Immunotherapeutic
- Form SCHEDULE 13G/A Scinai Immunotherapeutic Filed by: STONE DANIEL E.
- Form EFFECT Scinai Immunotherapeutic
- Form F-1 Scinai Immunotherapeutic
- Form 6-K Scinai Immunotherapeutic For: Sep 22
- Form 6-K Scinai Immunotherapeutic For: Sep 11
- Form EFFECT Scinai Immunotherapeutic
- Form POS AM Scinai Immunotherapeutic
- Form 6-K Scinai Immunotherapeutic For: Jun 30
- Form 6-K Scinai Immunotherapeutic For: Jun 12
